Bruttomesso et al. have proven that young adults with type 1 diabetes are characterized by better metabolic control, lower glucose variability, fewer hyperglycaemic episodes, less daily insulin dose, and lower free fatty acids when treated with CSII as compared to those treated with MDI. Here, INS is linked to type 1 diabetes mellitus.